Cargando…

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment

BACKGROUND: Injectable opioid agonist treatment (iOAT) was designed as a pragmatic and compassionate approach for people who have not benefitted from medication assisted treatment with oral opioids (e.g., methadone). While, a substantial body of clinical trial evidence has demonstrated the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchand, Kirsten, Foreman, Julie, MacDonald, Scott, Harrison, Scott, Schechter, Martin T., Oviedo-Joekes, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971856/ https://www.ncbi.nlm.nih.gov/pubmed/31959189 http://dx.doi.org/10.1186/s13011-020-0253-y

Ejemplares similares

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
por: Palis, Heather, et al.
Publicado: (2021)

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2012)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder()
por: Palis, Heather, et al.
Publicado: (2018)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
por: Jaffe, Kaitlyn, et al.
Publicado: (2023)

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
por: Palis, Heather, et al.
Publicado: (2017)

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2019)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2021)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Patient-centred care for addiction treatment: a scoping review protocol
por: Marchand, Kirsten, et al.
Publicado: (2018)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
por: Marchand, Kirsten, et al.
Publicado: (2019)

The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users
por: Marchand, Kirsten, et al.
Publicado: (2015)

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency
por: Marchand, Kirsten I, et al.
Publicado: (2011)

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
por: Fikowski, Jill, et al.
Publicado: (2014)

A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America
por: Gartry, Candice C, et al.
Publicado: (2009)

A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study
por: Trujols, Joan, et al.
Publicado: (2014)

Importance of Opioid Agonist Therapy to Reduce Injection-Related Infections
por: Weaver, Victoria K, et al.
Publicado: (2022)

Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report
por: Patricelli, Charissa J., et al.
Publicado: (2023)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
por: Russell, Cayley, et al.
Publicado: (2022)

Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
por: Bech, Anne Berit, et al.
Publicado: (2019)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series
por: Patricelli, Charissa J., et al.
Publicado: (2023)

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review
por: Rice, Danielle B, et al.
Publicado: (2018)

Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013–2017): a prospective cohort study
por: Vold, Jørn Henrik, et al.
Publicado: (2020)

The Cedar Project: resilience in the face of HIV vulnerability within a cohort study involving young Indigenous people who use drugs in three Canadian cities
por: Pearce, Margo E., et al.
Publicado: (2015)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

Unpacking Vaccine Hesitancy Among Healthcare Providers
por: MacDonald, Noni E., et al.
Publicado: (2015)

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans
por: Eydt, Erin, et al.
Publicado: (2021)

Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index
por: Perea-Milla, Emilio, et al.
Publicado: (2009)

Scoping review protocol: the use of telemedicine in providing opioid agonist treatment and related psychosocial supports
por: Crowley, Des, et al.
Publicado: (2020)

Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences
por: McDonald, Rebecca, et al.
Publicado: (2023)

Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study
por: Kranzler, Henry R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ob04ci12h8cd7sgrlh1ttbkrj5